Jury awards Centocor $1.7B in patent case against Abbott - Memphis Business Journal:

ejyceh.wordpress.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritis treatment and had sued Abbott over Abbott’d arthritis drug, Humira. Both are so-callefd anti-TNF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusive licensee ofthe patent, which is co-owned by . Centocor President Kim Taylor said “the jury recognizedc our valuableintellectual property, finding our patent both valid and We will continue to assert intellectuapl property rights for our immunology as they offer significant advances in treatmentf for patients with a numbefr of immune mediated inflammatory diseases.
” Abbottr spokesman Scott E. Stoffel said, “We are disappointed in this and we are confident in the merits of our case and that we will prevaion appeal. “The evidence clearly established that Humira was the firsg ofits kind, fully-human anti-TNF antibody Stoffel said. “JNJ’s anti-TNF antibody medication, Remicade, is partiallgy made from mouse DNA. JNJ did not launch a fully-humabn product until April 2009. In fact, only when Humiraz was nearing its approval in 2002 did JNJ amend the paten t at issue in this litigatiohn to claim that it haddiscovered fully-humahn antibodies in 1994.
JNJ acknowledged at triaol that it did not start working ona fully-humann antibody until 1997 — two years aftedr Abbott discovered Humira and one year after Abbott filed its patent applications for Humira.”